Topics

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 32, Status: Authorised

10:24 EST 18 Jan 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 32, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 32, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections,Immunization, Date of authorisation: 09/12/2009, Revision: 32, Status: Authorised"

Quick Search

Relevant Topics

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...